Trial readouts
What the latest Phase 2 and Phase 3 trials reported, the effect sizes that matter, and how to read the safety signals around them.
Semaglutide in One BBS10 Case
One woman with BBS10-related Bardet-Biedl syndrome had improved metabolic markers over six months, but a case report cannot prove efficacy.
Semaglutide equity model explained
A 25-year semaglutide model weighed cost per QALY against projected equity for older adults with obesity and cardiovascular disease.
STRIDE: Semaglutide and PAD Walking
STRIDE found that semaglutide improved walking capacity in adults with type 2 diabetes and symptomatic peripheral artery disease.
Tirzepatide During ECT: One Case
One patient taking tirzepatide completed 17 ECT sessions without complications, but the case report cannot establish a safe protocol.
Tirzepatide and Migraine: Two Cases
Two patients reported fewer migraine days on tirzepatide, but weight loss and an uncontrolled design prevent causal conclusions.
Tirzepatide Ocular Study: What We Know
A letter on tirzepatide ocular outcomes has no public abstract. The underlying cohort found associations, not proof of eye protection.
Vutiglabridin and Semaglutide in Mice
A preclinical mouse study found more fat loss with vutiglabridin plus semaglutide, but it provides no evidence of human efficacy.
Asthma Biologic Injection Pain
A multicenter observational study linked injection pain during severe-asthma biologic treatment with higher treatment-aversion scores.
Tirzepatide vs SGLT2 Drugs in MASLD
A matched MASLD cohort linked tirzepatide to fewer deaths and liver events than SGLT2 inhibitors, but it cannot prove superiority.
GIP Agonists and Blockers in Obesity
A 2026 review asks why GIP receptor agonists and blockers can both support weight loss, then separates mouse mechanisms from human trial evidence.
GLP-1 Drugs and Sleep Apnea
A six-trial meta-analysis linked GLP-1-based therapies to fewer apnea events, but high heterogeneity limits the pooled estimate.
REDEFINE 3: CagriSema Trial Design
REDEFINE 3 has published its CagriSema trial design and baseline cohort, but cardiovascular outcome results remain pending.